GlaxoSmithKline agrees to $750 million settlement
After knowingly selling drugs with questionable safety for years, drug maker GlaxoSmithKline has agreed to a $750 million settlement.
GlaxoSmithKline plc today announced that it has commenced its previously announced tender offer to acquire all of the outstanding shares of Human Genome Sciences for US$13.00 per share in cash.